BLUE SAIL MEDICAL CO.,LTD.

Blue Sail Medical Co., Ltd. is a leading multinational medical device company established in 2002 and listed on the Shenzhen Stock Exchange in 2010. The company specializes in the manufacturing of high-value and medium-low value consumables, focusing on various medical applications. Its product offerings include cardiovascular devices, health protection products, and emergency rescue equipment, positioning Blue Sail Medical as a significant player in the medical device sector. The company's main business lines encompass three key divisions: the cardiovascular division, which develops and produces devices for coronary intervention and structural heart diseases; the health protection division, centered on disposable gloves for medical and industrial use; and the emergency rescue division, which focuses on first aid kits and related products. Blue Sail Medical has established a comprehensive industrial layout that integrates high-value and low-value products, leveraging its research and development capabilities to maintain a competitive edge in global markets. The company is committed to innovation and has developed a robust pipeline of products, enhancing its market position across various medical fields.

1. The company has established an industrial layout integrating high-value and low-value products, with each business segment having a leading position in global competition. Focusing on the medical device field, the company has delved into vertical niche markets and built a multi-business segment layout featuring complementary models and risk hedging through the combination of high-value and low-value consumables. After years of transformation and upgrading, it has evolved from a low-value consumables enterprise mainly producing medical gloves to a leading medical device company covering areas such as cardiovascular and cerebrovascular, health protection, and emergency rescue. 2. The company's outstanding product innovation capabilities have established a platform-based matrix of existing products and R&D pipelines, laying a solid foundation for long-term performance growth. (1) Cardiovascular and Cerebrovascular Division: The company consistently launches new products, driving the entry of regular products into hospitals with blockbuster products and promoting rapid business growth with innovative products. It has deeply engaged in areas such as coronary intervention and structural heart diseases, maintaining high-level and efficient R&D investment, and has formed a high-quality R&D pipeline. (2) Health Protection Division: The company has been deeply involved in the health protection field for many years. In the first half of 2025, it added new products such as medical examination gloves and low-zinc food-grade nitrile gloves. Blue帆Medical has been recognized as a provincial manufacturing single champion； its subsidiary， Shandong Health Technology， has received multiple honors and awards including high-tech enterprise， contribution award for scientific and technological innovation development， and contribution award for key project construction； its subsidiary， Shandong Blue帆New Materials Co.， Ltd.， has been recognized as a high-tech enterprise. (3) Emergency Rescue Division： The company's emergency rescue products mainly consist of first aid kits and bags， which have obtained EU CE certificates， MDSAP certificates from Australia and Canada， and FDA certifications from the United States. Its subsidiary， Hubei Gaode， has received multiple honors and certifications including high-tech enterprise， provincial specialized， refined， distinctive， and innovative small and medium-sized enterprise， provincial high-quality development enterprise， provincial green manufacturing factory， and 2024 provincial manufacturing single champion enterprise. The company continuously optimizes first aid kit products， developing more humanized， efficient， creative， and scene-specific emergency rescue products to enhance the richness of its product line. (4) External Investment and Incubation Field： In the cardiovascular and cerebrovascular field， the company has extended its layout through equity participation in products such as ventricular assist devices (VAD) and optical coherence tomography (OCT)， and has invested and incubated in related tracks such as neurointervention and peripheral intervention. This is aimed at continuously enhancing the company's comprehensive competitive strength in high-value cardiovascular and cerebrovascular consumables， improving the cross-segment market platformization capabilities of the cardiovascular and cerebrovascular division， and building a solid product innovation barrier. As of June 30， 2025， the company's incubated neurointervention business segment has had 7 products approved， and the company's incubated peripheral intervention business segment has had 6 products approved. 3. The company's ability to gather global top resources for R&D has achieved internationally leading technological R&D capabilities， helping the company build long-term technological barriers. (1) Global collaborative R&D， building a 24-hour two-way interactive innovation system： The company has established R&D and clinical registration platforms in multiple core regions around the world， with over 540 patents. Relying on global R&D resources， clinical data from top hospitals at home and abroad， and the practical experience of the domestic R&D team， it has established a two-way interactive R&D mechanism between international and domestic. This mechanism not only introduces overseas technologies but also promotes Chinese independent technologies to go global， forming an innovative model of coordinated development between internationalization and localization. (2) Leading innovation research in the industry， with global recognition of technology and academic influence： The company is a medical device enterprise with complete independent intellectual property rights in the cardiovascular and cerebrovascular field in China. Its core technologies， products， and clinical achievements have been published in multiple top international academic journals and widely recognized by the industry. (3) Always adhering to innovation-driven high-quality development， committed to creating new quality productivity. After 20 years of development, the company has grown into a multinational platform enterprise with globalized R&D, clinical trials, manufacturing, and internationalized talents, focusing on the strategic emerging industry of high-end medical devices and integrating high-tech attributes into its manufacturing genes. 4. A global customer base and sales coverage, along with channel reuse among various sub-sectors, promote business growth while mitigating external risks. The company has implemented a global localization strategy, combining direct sales and distribution, offline and online sales, and adopting efficient market access, innovative marketing, and multi-channel cooperation to build an industry-leading sales network. Leveraging its "high-value + low-value" integrated medical device industrial platform, it has successfully achieved cross-industry collaborative sales. Through resource sharing and complementary advantages among various business units, it provides customers with one-stop surgical instruments and consumables products and solutions, continuously enhancing customer loyalty. 5. Localized production in multiple regions worldwide, insistence on autonomous and controllable supply chains, and continuous integration and optimization of production facilities lay a solid foundation for profit growth. The cardiovascular division has fully localized its international business production overseas, with coronary products manufactured in Singapore and structural heart disease products produced in Germany and Singapore. This enables independent production and supply in China, Europe, and Southeast Asia, effectively addressing potential trade protectionism in various countries and ensuring supply chain stability. The health protection and emergency rescue divisions have continuously improved production technology and integrated production capacity, achieving sustained efficiency improvements and lean, low-cost operations. 6. The core corporate culture of "openness, inclusiveness, standardization, and co-creation" attracts global talents and partners, facilitating long-term and sustainable development. The company adheres to the new era of socialism with Chinese characteristics, drawing wisdom from traditional Chinese culture and Shandong Qi culture to cultivate a distinctive Blue帆 Medical corporate culture： "openness， inclusiveness， standardization， and co-creation". The core management team has long been engaged in related industries， possessing profound industry technical and development insight capabilities.